From the Research
In patients with cirrhosis, the preferred proton pump inhibitor (PPI) is esomeprazole, particularly for those with severe hepatic impairment (Child-Pugh C), due to its safety profile and recommended maximum dosage of 20 mg per day. This recommendation is based on the study by 1, which classified esomeprazole as having 'no additional risks known' and recommended its use in patients with CTP C cirrhosis.
When considering the use of PPIs in cirrhotic patients, it is essential to weigh the benefits against the potential risks, including the development of infections and hepatic encephalopathy, as noted in 1 and 2. The study by 3 highlighted the concerning overprescription of PPIs in cirrhotic patients, often deviating from established guidelines, which subjects patients to unnecessary risks.
Key points to consider when prescribing PPIs to patients with cirrhosis include:
- Using esomeprazole, omeprazole, or rabeprazole in patients with CTP A or B cirrhosis, as suggested by 1
- Limiting the use of PPIs to patients with clear indications, such as gastroesophageal reflux disease, peptic ulcer disease, or prophylaxis in specific high-risk scenarios
- Prescribing PPIs for the shortest duration necessary to minimize the risk of complications
- Regularly reassessing the need for continued PPI therapy every 3-6 months in these patients
It is crucial to prioritize the safety and well-being of patients with cirrhosis when prescribing PPIs, taking into account their individual needs and the potential risks associated with these medications, as emphasized by 2 and 3.